Genetic Medicine:

Page 11234..1020..»

Personalized Medicines Market : Latest Trends,Analysis & Insights 2023 – Digital Journal

This press release was orginally distributed by SBWire

Albany, NY — (SBWIRE) — 02/20/2017 — Personalized medicine is a concept that has the potential to transform medical interventions by providing effective and tailored therapies. The development of personalized medicine is a novel approach to introduce new dimension in medicine and healthcare industries. It includes the use of molecular analysis to achieve optimal medical outcome in management or diagnosis of patient’s disease. The main objective of personalized medicine is to identify most appropriate treatment option for patient population.

Download Exclusive Brochure of This Report :

http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=394

The market of personalized medicines and pharmacodiagnostics can be segmented as below:

By Therapeutics Cancer Management Tissue-based Tests Blood Markers Circulating Tumor Cells Infectious Diseases HIV HBV HCV Hospital Acquired Infections Coagulation Therapy Autoimmune Diseases Cardiovascular Diseases CNS Disorders Diabetes Blood Transfusion Safety By Diagnostics By Theranostics By Application Pharmaceutical Diagnostics Healthcare Others The market of personalized medicine is witnessing positive growth owing to the advancement in technologies coupled with introduction of new technologies by key players. For example, in June 2013, Natural Molecular Testing Corporation launched expanded cardiac personalized medicine based on Luminex Corporation’s xMAP technology. In addition, introduction of technologies like NanoVelcro chip devices and gene therapies by using pill for treating cancer will increase the customer base for personalized medicines and hence stimulates the market growth. Furthermore, personalized medicines have increased the possibility of healthcare profits, safety of patients and improve the clinical results which will further drive the growth of the market of pharmacodiagnostics and personalized medicines. For example, personalized medicines offer cost-effective treatment and also eliminate overspending for the cancer treatment. This factor would ultimately attract more number of customers to use personalized medicines and hence drives the market growth. Moreover, various other factors like early diagnosis of diseases, high adverse reaction of prescription drugs, changing patient’s trend and patient compliance would also augment the market growth. Furthermore, personalized medicines have major impact on small to medium sized enterprises (SMEs). It offers great business opportunities for these companies to develop their industrial boundaries across the globe. Thus, all the above mentioned factors would increase the use of personalized medicines by SMEs and hence further augments the market growth. However, implementation of personalized medicines in biomedical research and in clinical applications is still at a low pace which might restrict the growth of this market.

Geographically, North America dominates the global personalized medicines market. Advancement in technologies and increasing research activities on human DNA by various biotechnology companies in North America will drive the market growth. In addition, increasing incidence and prevalence of cancer and cardiovascular diseases in North America further drives the market growth. Europe is considered as the second largest market of personalized medicines. The growth of personalized medicines market in Europe is mainly attributed to consistent efforts of private research institutes and government for the development of clinical application for cancer, heart diseases and neurodegenerative disorders. Asia-Pacific region is considered as an emerging market for personalized medicines owing to ability of personalized medicines to provide cost effective and safer treatment options.

The leading players competing in personalized medicines market are Bayer HealthCare Pharmaceuticals, Abbott Molecular, Inc., Celera Diagnostics, Hologic, Inc., Rosetta Genomics Ltd., Macrogen, Inc., IRIS Personalized Medicine, Bristol-Myers Squibb, Cepheid, Curagen Corp., Decode Genetics, Exagen Diagnostics, Dako Denmark A/S, Exact Sciences Corp. and others.

Browse Global Strategic Business Report:

http://www.transparencymarketresearch.com/personalized-medicines-market.html

This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. This report provides comprehensive analysis of

Market growth drivers Factors limiting market growth Current market trends Market structure Market projections for upcoming years

For more information on this press release visit: http://www.sbwire.com/press-releases/personalized-medicines-market-latest-trendsanalysis-insights-2023-772483.htm

More:
Personalized Medicines Market : Latest Trends,Analysis & Insights 2023 – Digital Journal

Read the Rest...

TiGenix hires Lonza to make cell therapy for Crohn’s complications – BioPharma-Reporter.com

TiGenix is using Lonza as a US CMO and Takeda as an ex-US commercialization partner to launch and trial its off-the-shelf stem cell therapy for a complication of Crohns disease.

TiGenix NV is a Belgian biotech developing a Phase III cell therapy Cx601 for a complication of Crohns Disease which has been licensed ex-US to Takeda Pharmaceutical Company Ltd.

Cx601 is based on stem cells taken from donor adipose tissue, as an allogenic off-the-shelf cell therapy product for the treatment of complex perianal fistulas in patients with Crohns disease patients who do not otherwise respond to standard therapies.

According to new data released today from thepivotal Phase III trial , Cx601 has reached its primary endpoint: long term remission ofperianal fistulas in patients with Crohns disease.

Wilfried Dalemans, CTO of TiGenix, told Biopharma-Reporter that TiGenix is also working with Lonza to facilitate a new trial for registering Cx601 in the states.

[Lonza] is now introducing our manufacturing process into their facilities in the US. Once the tech transfer is completed, they will produce clinical material,he told us.

TiGenix is developing Cx601 in the States after an agreement with the US FDA based on a special protocol assessment procedure (SPA) in 2015. Dalemans added:This is the first time we’re working with a CMO in the US.

For the pivotal Phase III trial for Cx601 in the US, TiGenix will use the services of a US-based contract manufacturing organization, Lonza. This trial is expected to begin in the first half of 2017, and the firm has already begun the process of transferring our technology to them for the purpose to this trial.

Manufacturing Cx601

The Cx601 therapies are manufactured in a 2-dimensional cell culture in CF5, and according to Dalemans, do not yet need more sophisticated reactors.

To meet the manufacturing capacity for the European launch of Cx601, the current GMP facilities in Madrid are currently being expanded with the 50-50 financial support of Takeda.

Dalemans told us:We’re using local service providers for the engineering of the facility extension. For the equipment, we are at this stage still selecting who we will use to supply instruments like incubators and laminar flows etc.

From the manufacturing site, the products arepackaged in special containers to maintain a temperature between 15 25 degrees centigrade for transport to the clinical site.

Cx601 is a living product – a suspension of living cells kept at room temperature. Because its not a frozen product, we do indeed need a cold chain supplier,he explained.

Takedas advice

Last July last year TiGenix partnered with Takeda to give the big pharma firm exclusive rights to commercialize Cx601 for complex perianal fistulas outside the US.

Luke Willats, a spokesperson for Takeda, told us:Takeda is a global leader in gastroenterology, [so] the acquisition of Cx601 is just a dedication and commitment to GI – and the related complications.

For these reasons, Takeda and TiGenix are working very closely in anticipation of the EMA approval, expected in the second half of 2017.

Dalemans explained: We’re expanding our current Madrid facility to meet the capacity that will be needed once Takeda begins to commercialise Cx601 – we’re also working closely with Takeda for even further extension of the capacity.

Willats told us that once authorization by the European regulators is obtained, Takeda will assume commercialization for Cx601 outside of the US.

Excerpt from:
TiGenix hires Lonza to make cell therapy for Crohn’s complications – BioPharma-Reporter.com

Read the Rest...

Local vet taking part in stem cell therapy study for dogs – Story … – ABC Action News

TARPON SPRINGS, Fla. – Cosby just doesnt get around like he used to.

We have six dogs and hes always the one thats the last to get up. The last to get out, said his owner Brian Cirillo.

And for Cirillo, its sad to see.

I hate it. Its always like he always on his tippy topes on his back legs. So its heartbreaking.

But a new trial study that is about to start at the St. Francis Pet Care Center in Tarpon Springs, could be just what Cosby needs.

Veterinarian Mike Amsberry is offering stem cell therapy for dogs.

They are seeing that its very, very safe. And very effective.

This study is focused specifically on four-legged friends with arthritis.

But in the past hes seen stem cell treatments work wonders for other ailments.

Its cells treating the body, rather than then some foreign substance. Some medication.

In this trial, the stem cells come from umbilical cords of donor dogs.

Not only can qualified pets get the treatment for free, but owners are paid too.

Cosby seems like the perfect candidate.

I think thats where everything seems to be going with regard to medicine. So to be on the leading edge of that to potential help him without having to put him on a bunch of medicine is definitely a plus, said Cirillo.

The hope is one day Cosby will be able to keep up with the rest.

And lead the way to help thousands of other dogs.

For more information on the trial study go to petstemcells.org.

See the rest here:
Local vet taking part in stem cell therapy study for dogs – Story … – ABC Action News

Read the Rest...

AJ Foyt planning to undergo stem cell therapy – USA TODAY

A.J. Foyt during practice for the 2016 Indianapolis 500. (The Indianapolis Star)

Auto racing legend A.J. Foyt is hoping to find thefountain of youth for a body that has taken quite a beating over the years. And like a handful of athletes before him, its a journey that will take him outside the United States.

Foyt, 82, told IndyCar.com Saturday during a Verizon IndyCar Series test at Phoenix International Raceway that he plans to undergo stem cell therapy, likely in Cancun, Mexico, with injections into both ankles and shoulders as well as his blood.

Foyt suffered a broken back during a NASCAR race in 1964 and broken feet and legs during a 1991 IndyCar crash. In 2005, hewas stung more than 200 times by bees while trapped under his bulldozer at his Texas ranch. Hes had knee and hip replacements, and in 2014 underwent triple-bypass heart surgery.

Hes hopeful that stem cell therapy will help heal the lingering effects of some of those ailments.

They have to cut away some of the tissue from my stomach and it takes 8-10 weeks for it to grow back to produce the stem cells, Foyt told IndyCar. Ill probably have it done soon so that we can begin the treatment within the next two to three months.

Adult stem cells are able to grow and become a cell for a specific tissue or organ, according to the National Institutes of Health. They are different from embryonic stem cells, which come from fertilized eggs or aborted fetuses. Embryonic stem cells can turn into cells for nearly any tissue in the body.

But the procedure Foyt seeks has not yet been approved by the FDA for use in the United States, so he will head south of the border where several former football players have received these treatments.

MORE:Companies offer athletes hope with questionable stem cell treatments

It used to be you would have to go to Germany to get this procedure, but now its available in Cancun and that is probably where Ill have it done, Foyt said. Dan Pastorini (the former NFL quarterback) did it and it helped him. Peyton Manning (the former Indianapolis Colts and Denver Broncos quarterback) did it for his neck and it really helped him. Tony Dorsett (the former Dallas Cowboys running back) did it, so I think we should try it.

Dorsett underwent a procedure where stem cells were extracted from his own stomach fat then cultured and multiplied with the help of a serum derived from cattle. The cells were then purified and injected back into him, about 200 million at a time, in Cancun.

When I was taking the stem cells, I was able to figure things out a little better and not get as frustrated, Dorsett told USA TODAY Sports in November of 2015. But Dorsett also admitted the effects of the therapy faded over time.

Stem cell treatments are largely untested and unproven by U.S. standards. In general, the FDA has a critical threshold for adult stem cell therapies.

If the cells are more than minimally manipulated when extracted from a patients body, they are classified as biological drugs that must go through long and costly testing to make sure they are safe and effective for widespread use in the USA.

Contributing:Brent Schrotenboer and Jarrett Bell

Read more:
AJ Foyt planning to undergo stem cell therapy – USA TODAY

Read the Rest...

Multiple sclerosis: Stem cell transplantation may halt disease progression – Medical News Today

New research provides further evidence of autologous hematopoietic stem cell transplantation as an effective treatment for multiple sclerosis, after finding the procedure halted disease progression for 5 years in almost half of patients.

Lead study author Dr. Paolo Muraro, of the Department of Medicine at Imperial College London in the United Kingdom, and colleagues recently reported their findings in JAMA Neurology.

The results come just a fortnight after another study revealed the success of a similar treatment in a small group of patients with relapsing-remitting multiple sclerosis (RRMS).

However, Dr. Muraro and team warn that further trials are needed to determine the efficacy and safety of autologous hematopoietic stem cell transplantation (AHSCT), after a small number of patients died within 100 days of treatment.

In AHSCT, a patient’s own stem cells are harvested. The patient is then subject to high-dose chemotherapy to eliminate any diseased cells.

Next, the harvested stem cells are returned to the patient’s bloodstream, with the aim of restarting normal blood cell production. In simple terms, AHSCT “resets” the immune system.

“We previously knew this treatment reboots or resets the immune system – and that it carried risks – but we didn’t know how long the benefits lasted,” notes Dr. Muraro.

For their study, the researchers assessed data from 25 treatment centers across 13 countries, identifying 281 patients with multiple sclerosis (MS) who underwent AHSCT between 1995-2006. Of these patients, 78 percent had a progressive form of MS.

Using the Expanded Disability Status Scale (EDSS), the team evaluated patients’ progression-free survival at 5 years after treatment and any improvements in MS symptoms.

An EDSS score of zero represents no disability, seven represents the use of a wheelchair, while 10 represents death from MS. At the beginning of the study, patients had an average EDSS score of 6.5.

Overall, the researchers found that 46 percent of patients experienced no disease progression in the 5 years after treatment.

Patients with RRMS – characterized by inflammatory attacks, or “flare-ups,” followed by periods of remission – had the best outcomes, with 73 percent experiencing no worsening of symptoms in the 5 years after AHSCT.

Additionally, patients experienced small improvements in MS symptoms after AHSCT. Patients with progressive MS saw their EDSS score rise by 0.14 a year after treatment, while patients with RRMS experienced a 0.76 increase in their EDSS score.

Patients with a younger age, few immunotherapies prior to AHSCT, and a lower EDSS score at study baseline also showed better outcomes with AHSCT.

While these findings show promise for the use of AHSCT for patients with MS, the team notes that there were eight deaths in the 100 days after AHSCT, which were thought to have been treatment related.

AHSCT involves aggressive chemotherapy, which can severely weaken the immune system and increase susceptibility to infection.

“In this study, which is the largest long-term follow-up study of this procedure, we’ve shown we can ‘freeze’ a patient’s disease – and stop it from becoming worse, for up to 5 years.

However, we must take into account that the treatment carries a small risk of death, and this is a disease that is not immediately life-threatening.”

Dr. Paolo Muraro

Dr. Muraro notes that, importantly, this study did not include a group of MS patients who did not receive treatment, further highlighting the need for more studies assessing the safety and efficacy of AHSCT.

“We urgently need more effective treatments for this devastating condition, and so a large randomized controlled trial of this treatment should be the next step,” he adds.

Read about a study that links vitamin D level at birth to the risk of MS.

Continue reading here:
Multiple sclerosis: Stem cell transplantation may halt disease progression – Medical News Today

Read the Rest...

Page 11234..1020..»